Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nanosphere's respiratory virus subtyping test gets FDA go-ahead

This article was originally published in Clinica

Executive Summary

A test developed by Nanosphere to detect different types of respiratory viruses has received 510(k) clearance from the US FDA. The Verigene respiratory virus plus nucleic acid test (RV+) can identify influenza A and B, and respiratory syncytial virus (RSV) A and B. It also further classifies influenza A infections as H1, H3 or the 2009 H1N1 subtype. The test runs on the firm's Verigene system. The RV+ automates several testing steps including viral RNA extraction, multiplexed RT-PCR amplification and target detection, and only requires a single pipetting step. Northbrook, Illinois-based Nanosphere claims the product offers "the broadest respiratory panel available".

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096490

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel